GreenBone Ortho

Executive Summary

GreenBone Ortho is an Italian medical device company pioneering a novel class of bone graft substitutes derived from rattan wood. Its lead product, b.Bone, is a CE-marked bioactive scaffold that mimics the structure of natural bone, promoting osteoconduction and remodeling. The technology addresses a significant unmet need in orthopedic and trauma surgery, where autografts are limited and synthetic alternatives often lack bioactivity. With a strong IP portfolio and growing clinical evidence, GreenBone is positioned to capture share in the global bone graft market, valued at over $3 billion. The company has completed initial clinical studies demonstrating safety and efficacy in spinal fusion and long bone defects, and is now scaling manufacturing and pursuing regulatory approvals in key markets. Despite being privately held with limited disclosed financials, GreenBone's innovative approach and clear clinical pathway suggest promising upside for strategic partners or investors.

Upcoming Catalysts (preview)

• Q1 2027FDA IDE Submission for US Clinical Trial60% success
• Q4 2026Strategic Partnership with Major Orthopedic Company50% success
• Q3 2026Publication of 2-Year Clinical Data in Spinal Fusion80% success